Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,775 shares of the company's stock after selling 6,698 shares during the quarter. Dimensional Fund Advisors LP owned about 0.23% of Revolution Medicines worth $16,961,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. IFP Advisors Inc bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $34,000. Sterling Capital Management LLC lifted its holdings in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after purchasing an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in Revolution Medicines by 521.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock worth $165,000 after buying an additional 3,178 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in Revolution Medicines in the 4th quarter worth about $173,000. Institutional investors own 94.34% of the company's stock.

Insider Activity

In related news, insider Mark A. Goldsmith sold 11,738 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the sale, the insider now directly owns 441,564 shares of the company's stock, valued at approximately $17,238,658.56. This represents a 2.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at $4,489,834.24. The trade was a 1.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,660 shares of company stock valued at $650,406. Company insiders own 8.00% of the company's stock.

Revolution Medicines Trading Down 3.2 %

Shares of NASDAQ:RVMD traded down $1.33 during trading on Friday, reaching $40.58. The stock had a trading volume of 1,621,977 shares, compared to its average volume of 1,491,361. The company has a market capitalization of $7.56 billion, a P/E ratio of -11.30 and a beta of 1.11. The firm's 50-day simple moving average is $37.36 and its 200 day simple moving average is $43.41. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period last year, the firm earned ($0.70) EPS. Equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RVMD has been the subject of several research reports. Wedbush reissued an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a report on Thursday. HC Wainwright lifted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Oppenheimer increased their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday. Needham & Company LLC reaffirmed a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research report on Thursday. Finally, Stifel Nicolaus reduced their price objective on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Revolution Medicines has a consensus rating of "Buy" and a consensus target price of $67.17.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.